止带方联合重组人干扰素治疗慢性宫颈炎合并高危型HPV感染的疗效观察

陈耿红; 王芝英

doi:10.16766/j.cnki.issn.1674-4152.000652

止带方联合重组人干扰素治疗慢性宫颈炎合并高危型HPV感染的疗效观察

doi: 10.16766/j.cnki.issn.1674-4152.000652

陈耿红^1, ,,
王芝英²

1. 象山县妇幼保健院妇科, 浙江宁波 315700;
2. 象山县人民医院妇科, 浙江宁波 315700

基金项目:

国家卫计委重大疾病防治科技行动计划项目(zx-01-c2015008)

详细信息

通讯作者:
陈耿红,E-mail:misenlin@163.com

中图分类号: R711.32;R271.1
计量
- 文章访问数: 107
- HTML全文浏览量: 13
- PDF下载量: 3
- 被引次数: 0
出版历程
- 收稿日期: 2018-07-14

Clinical effect of Zhidai decoction combined with recombinant human interferon in treatment of chronic cervicitis patients with high-risk HPV infection

CHEN Geng-hong^{1
, ,},
WANG Zhi-ying²

Department of Gynecology, Maternal and Child Health Care Hospital of Xiangshan, Ningbo, Zhejiang 315700, China

摘要

摘要: 目的观察止带方联合重组人干扰素治疗慢性宫颈炎合并高危型HPV感染的临床疗效。方法以338例慢性宫颈炎合并高危型HPV感染患者为研究对象，使用随机数字表将全部研究对象分为对照组(169例)和研究组(169例)，对照组患者给予重组人干扰素α2b栓治疗，研究组患者给予止带方联合重组人干扰素α2b栓治疗，观察治疗期间药物不良反应，记录症状改善及高危型HPV转阴情况，评价疗效水平，统计宫颈炎症复发情况。结果研究组药物不良反应发生率(5.32%)与对照组(3.55%)差异无统计学意义(P>0.05)；研究组患者治疗后血清TNF-α、IL-6和IL-8含量均显著低于对照组(P<0.05)；研究组患者治疗后白带量改善率、白带脓性改善率和高危型HPV转阴率(96.45%、97.04%和92.90%)均显著高于对照组(85.21%、86.39%和80.47%)，P<0.05；研究组患者宫颈炎总体治疗有效率(95.27%)显著高于对照组(82.25%)，P<0.05；研究组患者治疗后6个月和12个月宫颈炎症复发率(3.55%和8.88%)均显著低于对照组(10.06%和19.53%)，P<0.05。结论相较重组人干扰素单纯治疗，止带方联合重组人干扰素可显著改善慢性宫颈炎合并高危型HPV感染患者相关临床症状，提高疗效水平和高危型HPV转阴率，有效预防宫颈炎症复发，且安全性较高。
- 止带方 /
- 重组人干扰素 /
- 慢性宫颈炎 /
- 高危型HPV感染 /
- 临床观察
Abstract: Objective To observe the clinical effect of Zhidai decoction combined with recombinant human interferon in treatment of chronic cervicitis combined with high-risk HPV infection. Methods Total 338 cases of chronic cervicitis with high risk HPV infection were enrolled into this study and were divided into control group (n=169) and observation group (n=169) by the random number table. The patients in the control group were administrated with recombinant human interferon α2b suppository, while the patients in the observation group were treated with Zhidai decoction combined with recombinant interferon α2b suppository. The adverse drug reactions during the treatment were recorded. The improvement of leucorrhea and the changes of positive rate of high risk HPV were observed. The curative effect and the recurrence of cervicitis were statistically compared. Results There was no statistically significant in the incidence of adverse drug reactions between the observation group (5.32%) and the control group (3.55%), P<0.05. The levels of serum TNF-α, IL-6 and IL-8 in the observation group were significantly lower than those in the control group (P<0.05). The improvement rate of leucorrhea quantity, leucorrhea purulent and positive high risk type HPV (96.45%, 97.04% and 92.90%) were significantly higher than those in the control group (85.21%, 86.39% and 80.47%) at the end of treatment (P<0.05). The total effective rate of cervicitis in the observation group (95.27%) was significantly higher than that in the control group (82.25%), P<0.05. The recurrence rate on the 6th and 12th month after the treatment in the observation group (3.55% and 8.88%) was significantly lower than that of the control group (10.06% and 19.53%), P<0.05. Conclusion Compared with recombinant interferon therapy alone, Zhidai decoction combined with recombinant human interferon, with a high safety, can more effectively improve the clinical symptoms and curative effect of chronic cervicitis patients with high-risk HPV infection, decrease the positive of high risk type HPV infection, and prevent the recurrence of cervicitis.
- Zhidai decoction /
- Recombinant human interferon /
- Chronic cervicitis /
- High-risk HPV infection /
- Clinical observation